New York Times, March 6, 2026: FDA’s biologics chief Vinay Prasad is resigning, leaving FDA for the second time. This time his rejection of rare disease treatments angered industry, some rare disease patients, and Members of Congress. But NCHR’s Diana Zuckerman says Prasad’s focus on evidence was welcomed by researchers and advocates who were concerned about FDA’s approval of ineffective treatments.
Read More »News That Quotes Us & Our Work
We are often quoted in major newspapers and magazines, and on well-respected TV shows, radio programs, and websites where we share our opinion on issues that matter to you and your health. Stay up to date on health news and our take on it by reading the articles in this section.
FDA’s Hoeg Reportedly Trying To Hire Friend, Fellow Antidepressant Skeptic
BioSpace, March 5, 2026: FDA’s CDER Director Tracy Beth Høeg wants to hire her friend Adam Urato, whose citizen’s petition urges a boxed warning on the risks of SSRIs during pregnancy. Diana Zuckerman and others say Høeg’s work has no nuance and doesn’t want to hear differences of opinion.
Read More »Edwards’ request for broader TAVR Medicare coverage gets pushback
MedTech Dive, January 28, 2026: MedTech Dive quotes public comments to CMS for and against Medicare coverage of TAVR for asymptomatic patients, including NCHR’s and Steve Woloshin’s criticism of the published evidence and medical society support
Read More »5 topics to watch as MDUFA negotiations restart
MedTech Dive, Jan 13, 2025: MedTech outlines 5 key issues as MDUFA negotiations restart, including FDA staffing, device safety and effectiveness, and transparency. The article highlights growing concern from NCHR’s Diana Zuckerman and other patient and consumer groups that safety and effectiveness may receive less attention than faster device approvals.
Read More »These are the treatments dominating the business of living longer
Washington Post, January 12, 2026: NCHR is quoted in article about supporters and skeptics about longevity research and resulting products being sold, promoted, and supported by RFK’s HHS but not necessarily approved by FDA.
Read More »